A pooled analysis of the TRuE-V1/TRuE-V2 phase 3 trials has shown that ruxolitinib (Opzelura) can help repigment the skin in multiple body areas, with lasting effects even in difficult areas.
Commercializing Rare Disease Therapies Is Getting Tougher informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.
Ianalumab in Sjögren s syndrome: what can we learn from lupus trials? thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
The Potential for Pragmatic Trials to Reduce Racial and Ethnic Disparities in Kidney Disease asnjournals.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asnjournals.org Daily Mail and Mail on Sunday newspapers.